Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Effect of modified Wenyang Buxin decoction and routine therapy on cardiac function and serum levels of H-FABP, cTnI and Ang-2 in chronic heart failure patients

Chengsi Qian, Yan Sun

Department of Cardiology, Zhejiang Province Rongjun Hospital, Jiaxing, 314001, Zhejiang Province, China;

For correspondence:- Yan Sun Email: subo4e@163.com

Accepted: 26 April 2022 Published: 31 May 2022

Citation: Qian C, Sun Y. Effect of modified Wenyang Buxin decoction and routine therapy on cardiac function and serum levels of H-FABP, cTnI and Ang-2 in chronic heart failure patients. Trop J Pharm Res 2022; 21(5):1109-1115 doi: 10.4314/tjpr.v21i5.28

© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the effect of modified Wenyang Buxin decoction and routine therapy on cardiac function and serum levels of heart-type fatty acid binding protein (H-FABP), cardiac troponin-1 (cTnI) and angiopoietin-2 (Ang-2) in chronic heart failure (CHF) patients.

Methods: A total of 120 CHF patients admitted to Zhejiang Province Rongjun Hospital (from January 2019 - January 2020) were selected for this study. They were randomly but equally distributed into groups A and B. All patients were given routine therapy such as diuretic treatment and detumescence, while those in group A received 150 mL of modified Wenyang Buxin decoction daily, in addition to routine therapy. At 2 months after therapy, cardiac function indices, serum H-FABP, cTnI and Ang-2 levels, hemorheology indices, traditional Chinese medicine (TCM) syndrome scores, and Chinese questionnaire of quality of life in cardiovascular patients (CQQC) scores of the two groups were evaluated.

Results: After therapy, cardiac function indices, serum H-FABP, cTnI and Ang-2 levels, hemorheology indices as well as TCM syndrome score and CQQC score were significantly improved in group A, when compared with corresponding values in group B (p < 0.05).

Conclusion: Modified Wenyang Buxin decoction and routine therapy improves serum biomarker levels, cardiac function and quality of life, and relieves clinical symptoms of CHF in patients. Therefore, this treatment approach may be useful in the management of CHF patients.

Keywords: Wenyang Buxin decoction, Heart-type fatty acid binding protein (H-FABP), Cardiac troponin-1 (cTnI), Angiopoietin-2 (Ang-2), Chronic heart failure (CHF